A Kansas City startup, Trially, has secured $4.7 million in seed funding to enhance its AI-driven platform, which aims to expedite clinical trial recruitment and potentially save patient lives. The funding round was led by Flyover Capital with contributions from several other investors. Co-founder Kyle McAllister emphasized that the platform, through its AI solution “Margo,” seeks to bridge the gap between life-saving treatments and patients in need by matching them to clinical trials more efficiently.
The pharmaceutical industry faces significant delays in clinical trials due to recruitment challenges, costing over $600,000 daily. Trially’s approach not only identifies but also engages and enrolls eligible patients, addressing a longstanding issue in the field.
“Margo” offers three key features: Trially Match, which uses medical data to match patients to trials; Trially Connect, which pre-screens and enrolls qualified candidates; and Trially Intelligence, which provides analytics to identify suitable trials for patient populations.
The platform’s AI capabilities allow it to achieve a 95% screening accuracy, transforming a labor-intensive process into immediate enrollment opportunities. With the new funding, Trially plans to expand its platform’s reach across research sites and networks, aiming to prevent costly delays and improve patient access to critical treatments.
